Siu, L. L., Even, C., Mesía, R., Remenar, E., Daste, A., Delord, J., . . . Fayette, J. (2018). Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial. JAMA Oncol.
Chicago Style CitationSiu, Lillian L., et al. "Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial." JAMA Oncol 2018.
Cita MLASiu, Lillian L., et al. "Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC: The Phase 2 CONDOR Randomized Clinical Trial." JAMA Oncol 2018.